Gossamer Bio, INC 8-K filings

Gossamer Bio and Chiesi Group have entered a global collaboration to develop and commercialize seralutinib for pulmonary hypertension, including a $160 million upfront payment to Gossamer.

Gossamer Bio has appointed Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors, signaling a strategic expansion into pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Gossamer Bio announced its fourth quarter and full-year 2023 financial results, highlighted by the first patient dosed in the Phase 3 PROSERA study for pulmonary arterial hypertension (PAH) and the inclusion of Japanese sites in the trial.

Gossamer Bio has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.